Patient and HCT characteristics
| . | Arm 1 (n = 6) . | Arm 2 (n = 12) . | All (N =18) . |
|---|---|---|---|
| Age at start of treatment, y | 53 (25-67) | 69 (55-73) | 65 (25-73) |
| Sex | |||
| Female | 1 (17) | 3 (25) | 4 (22) |
| Male | 5 (83) | 9 (75) | 14 (78) |
| Race | |||
| White | 4 (67) | 12 (100) | 16 (88) |
| Asian | 1 (17) | 0 | 1 (6) |
| Pacific Islander | 1 (17) | 0 | 1 (6) |
| Ethnicity | |||
| Hispanic | 2 (33) | 1 (8) | 3 (17) |
| Non-Hispanic | 4 (67) | 11 (92) | 15 (83) |
| Baseline MF | |||
| Mild | 1 (17) | 0 | 1 (6) |
| Moderate | 4 (33) | 2 (17) | 6 (33) |
| Severe | 1 (17) | 10 (83) | 11 (61) |
| Disease status at baseline | |||
| No response/stable disease | 6 (100) | 11 (92) | 17 (94) |
| Progression from hematological | 0 | 1 (8) | 1 (6) |
| HCT comorbidity index | 1 (0-3) | 3 (1-5)* | 3 (0-5)† |
| Performance status | |||
| 80 | 0 (0) | 4 (33) | 4 (22) |
| 90 | 4 (67) | 7 (59) | 11 (61) |
| 100 | 2 (33) | 1 (8) | 3 (17) |
| MF type | |||
| Primary | 4 (67) | 9 (75) | 13 (72) |
| Secondary | 2 (33) | 3 (25) | 5 (28) |
| MF risk (DIPSS criteria) | |||
| High | 1 (17) | 3 (25) | 4 (22) |
| Intermediate-2 | 5 (83) | 9 (75) | 14 (78) |
| HLA | |||
| 7/8 | 1 (17) | 0 (0) | 1 (6) |
| 8/8 | 5 (83) | 12 (100) | 17 (94) |
| Donor type | |||
| Sibling | 2 (33) | 3 (25) | 5 (28) |
| Unrelated | 4 (67) | 9 (75) | 13 (72) |
| Donor/recipient CMV pre-HCT | |||
| Negative/negative | 1 (17) | 2 (17) | 3 (17) |
| Negative/positive | 2 (33) | 4 (33) | 6 (33) |
| Positive/negative | 0 (0) | 2 (17) | 2 (11) |
| Positive/positive | 3 (50) | 4 (33) | 7 (39) |
| CD34 dose | 6.0 (4.3-9.1) | 6.0 (3.9-8.6) | 6.0 (3.9-9.1) |
| Time from diagnosis to HCT, mo | 12.9 (3.0-30.8) | 27.2 (4.0-74.5) | 17.2 (3.0-74.5) |
| Time from diagnosis to treatment, mo | 12.6 (2.7-30.5) | 26.9 (3.7-74.2) | 17.0 (2.7-74.2) |
| . | Arm 1 (n = 6) . | Arm 2 (n = 12) . | All (N =18) . |
|---|---|---|---|
| Age at start of treatment, y | 53 (25-67) | 69 (55-73) | 65 (25-73) |
| Sex | |||
| Female | 1 (17) | 3 (25) | 4 (22) |
| Male | 5 (83) | 9 (75) | 14 (78) |
| Race | |||
| White | 4 (67) | 12 (100) | 16 (88) |
| Asian | 1 (17) | 0 | 1 (6) |
| Pacific Islander | 1 (17) | 0 | 1 (6) |
| Ethnicity | |||
| Hispanic | 2 (33) | 1 (8) | 3 (17) |
| Non-Hispanic | 4 (67) | 11 (92) | 15 (83) |
| Baseline MF | |||
| Mild | 1 (17) | 0 | 1 (6) |
| Moderate | 4 (33) | 2 (17) | 6 (33) |
| Severe | 1 (17) | 10 (83) | 11 (61) |
| Disease status at baseline | |||
| No response/stable disease | 6 (100) | 11 (92) | 17 (94) |
| Progression from hematological | 0 | 1 (8) | 1 (6) |
| HCT comorbidity index | 1 (0-3) | 3 (1-5)* | 3 (0-5)† |
| Performance status | |||
| 80 | 0 (0) | 4 (33) | 4 (22) |
| 90 | 4 (67) | 7 (59) | 11 (61) |
| 100 | 2 (33) | 1 (8) | 3 (17) |
| MF type | |||
| Primary | 4 (67) | 9 (75) | 13 (72) |
| Secondary | 2 (33) | 3 (25) | 5 (28) |
| MF risk (DIPSS criteria) | |||
| High | 1 (17) | 3 (25) | 4 (22) |
| Intermediate-2 | 5 (83) | 9 (75) | 14 (78) |
| HLA | |||
| 7/8 | 1 (17) | 0 (0) | 1 (6) |
| 8/8 | 5 (83) | 12 (100) | 17 (94) |
| Donor type | |||
| Sibling | 2 (33) | 3 (25) | 5 (28) |
| Unrelated | 4 (67) | 9 (75) | 13 (72) |
| Donor/recipient CMV pre-HCT | |||
| Negative/negative | 1 (17) | 2 (17) | 3 (17) |
| Negative/positive | 2 (33) | 4 (33) | 6 (33) |
| Positive/negative | 0 (0) | 2 (17) | 2 (11) |
| Positive/positive | 3 (50) | 4 (33) | 7 (39) |
| CD34 dose | 6.0 (4.3-9.1) | 6.0 (3.9-8.6) | 6.0 (3.9-9.1) |
| Time from diagnosis to HCT, mo | 12.9 (3.0-30.8) | 27.2 (4.0-74.5) | 17.2 (3.0-74.5) |
| Time from diagnosis to treatment, mo | 12.6 (2.7-30.5) | 26.9 (3.7-74.2) | 17.0 (2.7-74.2) |